查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1146376

低氧療法市場 - COVID-19 的增長、趨勢、影響和預測 (2022-2027)

Hypoxia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 90 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，缺氧療法市場預計將以 3.5% 的複合年增長率增長。

2019 年冠狀病毒病 (COVID-19) 會導致嚴重的低氧血症，加劇 COVID-19 的損害。此外，缺氧對 COVID-19 患者的確切影響尚不清楚。在 COVID-19 感染早期，一些 COVID-19 患者會出現一種稱為“無聲缺氧”的情況，據觀察，缺氧會加劇感染並加劇肺細胞破壞。 Coronavirus Disease-2019 中的無聲缺氧：它更危險嗎？”研究發現，缺氧會破壞 Coronavirus disease-2019 患者的肺細胞。一項回顧性隊列研究”，2022 年 6 月發表於 Lung India，表明大約 32% 至 65% 的 COVID-19 患者出現無症狀缺氧。此外，根據 2020 年 5 月發表在《歐洲醫學與藥學評論》上的一項題為“治療 COVID-19 患者缺氧的氧療策略和技術”的研究，早期氧療可有效治療 COVID-19 患者的缺氧因此，市場增長預計將受到 COVID-19患者對氧療需求增加的影響。

市場受到製藥行業研發活動增加和缺氧流行率上升的推動。根據這項研究，“在低收入和中等收入國家就診於醫療機構的兒科和成人患者中低氧血症的患病率：系統評價和薈萃分析的方案”發表於 2020 年 3 月的系統評價，12 歲兒童低氧血症的患病率：因此，缺氧患病率的增加預計會增加對疾病管理中治療選擇的需求，並推動市場增長。

此外，預計研發活動的增加將支持預測期內的市場擴張。根據 2021 年 2 月發表在 Critical Care 上的一項題為“頭盔 CPAP 治療 ICU 外缺氧性肺炎：一項觀察性研究”的研究，有有效的界面據說是頭盔。頭盔式 CPAP 可作為一種挽救生命的治療方法，提高患者的生存率。此外，增加研發支出預計將推動市場增長。根據美國研究與製藥製造商協會 (PhRMA) 2020 年 9 月的更新，PhRMA 成員公司在 2020 年的研發活動中投資了約 830 億美元。此外，根據同一消息來源 PhRMA，2020 年，生物製藥公司正在研發 260 多種針對各種疾病（包括 COVID-19）的疫苗。

因此，上述所有因素，例如缺氧患病率上升和研發活動增加，預計都將推動市場增長。然而，嚴格的政府法規和替代品的可用性可能會限制預測期內的市場增長。

主要市場趨勢

預測期內哮喘病有望健康增長

哮喘是世界上最普遍的疾病之一，可能是一種致命的疾病，會損害人的正常呼吸能力。哮喘是一種慢性疾病，它會收縮和拉伸肺部的氣道，導致反復出現氣短、支氣管痙攣和可逆性氣流阻塞。煙草使用也顯著增加，這加劇了哮喘症狀。此外，隨著工業化進程的推進，哮喘患者的數量也在不斷增加，未來對哮喘藥物的需求可能會增加。哮喘患者數量的增加預計將推動這一領域的增長。哮喘患病率和發病率的顯著增加導致患者數量增加，從而導致對這些藥物的需求增加。根據世界衛生組織 (WHO) 2021 年情況說明書，哮喘是一種主要的非傳染性疾病 (NCD)，影響兒童和成人。在全球範圍內，估計 2.62 億人將被感染，2020 年將有 461,000 人死亡。

此外，市場參與者增加的研發活動和產品發布被認為正在推動市場的增長。例如，2021年3月，GlaxoSmithKline PC將與IQVIA Pty Ltd合作開展第三項研究，以評估GSK3511294（Depemokimab）在患有嚴重未控制哮喘的成人和青少年中的療效和安全性，III期臨床試驗已經啟動。該研究計劃於 2023 年 10 月完成。同樣，2021 年 2 月，AstraZeneca PLC 將與Amgen Inc.合作開展第二項研究，以評估 5 至 11 歲以下哮喘兒童單次皮下注射（SC）劑量的 tezeperumab 的藥代動力學（PK）概況。 I期臨床試驗已經開始。該考試計劃於 2021 年 9 月結束。因此，上述因素預計將在預測期內推動分部增長。

因此，所有上述因素，例如哮喘患者缺氧患病率上升，預計將在預測期內推動市場增長。

預計在預測期內北美將佔據重要的市場份額

由於缺氧症的普遍存在、研發支出的增加以及個人可支配收入的增加，北美在全球缺氧症市場佔據主導地位。缺氧主要與哮喘、慢性阻塞性肺病和肺炎等呼吸系統疾病有關，而慢性阻塞性肺病和哮喘等疾病發病率的增加正在推動市場的擴大。例如，根據國家心肺血液研究所 2022 年 3 月的更新，美國每年有超過 1500 萬人患有慢性阻塞性肺病。慢性阻塞性肺病是美國第四大死因，是一個主要的絆腳石。

此外，根據 2021 年加拿大哮喘年度報告，估計每天有 317 名加拿大人被診斷出患有哮喘。每年有超過 70,000 人因哮喘發作而住院。哮喘是加拿大第三大常見慢性病，每年影響超過 380 萬加拿大人。哮喘和慢性阻塞性肺病的高患病率增加了對治療這些疾病的藥物的需求，推動了該地區的增長。

此外，各種機構不斷增加的研究和開發活動可能會推動市場的增長，預計將呈現高增長。例如，2022 年 8 月，Pgharmazz Inc（美國）獲得中央藥品監督管理局的研究藥物申請批准，在缺氧缺血條件下開展 Sovateltide 的二期臨床試驗。此外，2022 年 1 月，第一款用於醫療級連續氧氣監測的非侵入式可穿戴設備 OxiWear 籌集了 125 萬美元的資金。

因此，上述所有因素都有望在預測期內提振市場。

競爭格局

由於存在一些大型參與者，該市場是一個整合市場。隨著技術進步和產品創新不斷，中小型公司正在通過以具有競爭力的價格將新設備推向市場來增加其市場佔有率。市場參與者包括 Thermo Fisher Scientific Inc.、Resmed、Hamilton Medical、Merck KGaA、Spotlight Labs, LLC.、HypOxygen、PharmaShots 和 Hancock Medical Inc。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 缺氧的發生率增加
    • 激活研發
  • 市場製約因素
    • 存在嚴格的政府法規和替代產品
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按類型
    • 缺氧缺氧
    • 貧血缺氧
    • 停滯缺氧
    • 細胞毒性缺氧
  • 按疾病分類
    • 慢性阻塞性肺疾病 (COPD)
    • 肺炎
    • 支氣管哮喘
    • 其他
  • 最終用戶
    • 醫院/診所
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲

第六章競爭格局

  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Resmed
    • Merck KGaA
    • Spotlight Labs, LLC.
    • HypOxygen
    • Hancock Medical Inc.
    • Fisher & Paykel Healthcare Limited
    • Invacare Corporation
    • Natus Medical Incorporated
    • Getinge AB
    • Hamilton Company
    • Koninklijke Philips NV

第七章市場機會與未來趨勢

簡介目錄
Product Code: 92010

The Hypoxia Treatment Market is expected to grow at a registered CAGR of 3.5% during the forecast period.

Coronavirus disease-2019 (COVID-19) produces severe hypoxemia, exacerbating the COVID-19 damage. Furthermore, the precise impact of hypoxia on COVID-19 patients is uncertain. Early on in the COVID-19 infection, some COVID-19 patients develop a condition known as "silent hypoxia," and it has been observed that hypoxia may aggravate the infection and exacerbate lung cell destruction. According to the study titled "Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? A retrospective cohort study" published in the Lung India in June 2022, around 32% to 65% of COVID-19 patients developed silent hypoxia. Additionally, according to the study titled "Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients" published in the European Review of Medical and Pharmaceutical Science, in May 2020, early-stage oxygen therapy has the potential to treat hypoxia in COVID-19 patients As a result, the market growth is expected to impact by the rise in demand for oxygen therapy among COVID-19 patients.

The market is being driven by both an increase in research and development activity by the pharmaceutical industry and an increase in the prevalence of hypoxia. According to the study titled "The prevalence of hypoxemia among pediatric and adult patients presenting to healthcare facilities in low- and middle-income countries: protocol for a systematic review and meta-analysis" published in the Systematic Review in March 2020, the prevalence of hypoxemia in children under the age of 12 ranged from 2-23% in the low and middle incomes countries. Therefore, the increasing prevalence of hypoxia is anticipated to increase the demand for therapeutic options in the management of diseases, driving up the market's growth.

Additionally, rising R&D activity is anticipated to support market expansion over the forecast period. According to the study titled "Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study " published in the Critical Care in February 2021, an efficient interface for administering noninvasive continuous positive airway pressure (CPAP) is a helmet. Patients might profit from helmet CPAP as a life-saving treatment to increase survival. Moreover, growing research and development spending is expected to boost the market growth. As per the September 2020 update by the Pharmaceutical Research and Manufacturers of America (PhRMA), the PhRMA members had invested nearly USD 83 billion in R&D activities in 2020. Furthermore, as per the same source, more than 260 vaccines are in the pipeline by biopharmaceutical companies for various diseases, including COVID-19, as per PhRMA, 2020.

Thus, all aforementioned factors such as the rising prevalence of hypoxia and growing research and development activity expected to boost the market growth. However, stringent government regulation coupled with the availability of substitute products may restrain the market growth over the forecast period.

Key Market Trends

Asthma are Expected to Witness Healthy Growth Over the Forecast Period

Asthma is one of the most widespread illnesses in the world and a potentially fatal condition that impairs patients' ability to breathe normally. It is a chronic condition that tightens and stretches the lungs' airways, leading to recurrent episodes of shortness of breath, bronchospasm, and reversible airflow obstruction. In addition, there has been a significant increase in cigarette use, which aggravates asthma symptoms. Additionally, as industrialization has grown, so has the number of asthma cases, which could increase the demand for asthma medications in the future. The segment growth is anticipated to be boosted by the rising number of asthma cases. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2020 and caused 461,000 deaths.

Furthermore, increasing research and development activity and product launches by the market players are likely to boost the growth of the market. For instance, in March 2021, GlaxoSmithKline PC, in collaboration with IQVIA Pty Ltd, initiated a Phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial is expected to be completed in October 2023. Similarly, in February 2021, AstraZeneca PLC, in collaboration with Amgen Inc., initiated a Phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma. The trial is expected to be completed in September 2021. Thus, the aforementioned factors are expected to drive segment growth over the forecast period.

Thus, all aforementioned factors such as the rising prevalence of hypoxia in asthmatic patients expected to boost the market growth over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America dominates the global market for hypoxia because of the prevalence of hypoxia, rising research and development spending, and rising personal disposable income. hypoxia is majorly associated with respiratory diseases such as asthma, COPD, and Pneumonia and thus the rising incidence of conditions like COPD and asthma contributes to the market's expansion. For instance, according to the National, Heart, Lung, and Blood Institutes updates in March 2022, more than 15 million persons in the United States suffer from COPD each year. The fourth-leading cause of death in the United States was COPD, which is a significant cause of impairment.

Moreover, as per Asthma Canada Annual Report 2021, every day, an estimated 317 Canadians are diagnosed with asthma. Every year, asthma attacks cause over 70,000 hospitalizations. Asthma is the third most common chronic disease in Canada, affecting more than 3.8 million Canadians each year. The high number of patients affected by asthma and COPD increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.

Moreover, growing research and development activity by various institutes likely to propel the growth of the market is expected to witness high growth. For instance, in August 2022, Pgharmazz Inc (United States) received clearance for investigational drug application from the Central Drug Control Organization to conduct phase II clinical trials for Sovateltide in the condition of hypoxic ischemia. Additionally, in January 2022, OxiWear, the first non-intrusive wearable for medical-grade, continuous oxygen monitoring, raised USD 1.25 million in funding.

Thus, all above-mentioned factors are expected to boost the market over the forecast period.

Competitive Landscape

The market studied is a consolidated market owing to the presence of few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Thermo Fisher Scientific Inc., Resmed, Hamilton Medical, Merck KGaA, Spotlight Labs, LLC., HypOxygen, PharmaShots, Hancock Medical Inc. etc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Hypoxia
    • 4.2.2 Increasing Research and Development Activity
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulation Coupled with Availability of Substitute Product
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Hypoxic Hypoxia
    • 5.1.2 Anaemic Hypoxia
    • 5.1.3 Stagnant Hypoxia
    • 5.1.4 Histotoxic Hypoxia
  • 5.2 By Diseases Type
    • 5.2.1 Chronic Obstructive Pulmonary Disease (COPD)
    • 5.2.2 Pneumonia
    • 5.2.3 Asthma
    • 5.2.4 Others
  • 5.3 By End User
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Others
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.2 Europe
    • 5.4.3 Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.5 South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific Inc.
    • 6.1.2 Resmed
    • 6.1.3 Merck KGaA
    • 6.1.4 Spotlight Labs, LLC.
    • 6.1.5 HypOxygen
    • 6.1.6 Hancock Medical Inc.
    • 6.1.7 Fisher & Paykel Healthcare Limited
    • 6.1.8 Invacare Corporation
    • 6.1.9 Natus Medical Incorporated
    • 6.1.10 Getinge AB
    • 6.1.11 Hamilton Company
    • 6.1.12 Koninklijke Philips NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS